Milestone Pharmaceuticals Inc. (MIST) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.6x

Market Cap

$148.78M

MomentumView details →

1D Return

−1.24%

YTD Return

−40.10%

RSI (14)

56.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.6x

Market Cap

$148.78M

RSI (14)

56.1

MomentumView details →

1D Return

−1.24%

YTD Return

−40.10%

SummaryUpdated Jun 1, 2026

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a Canadian biopharmaceutical company founded in 2003 and headquartered in Montréal. The company went public in May 2019 and focuses exclusively on developing cardiovascular medicines for patients with heart rhythm disorders. Milestone is currently a clinical-stage company with no approved products on the market, dedicating its resources to advancing its lead drug candidate etripamil through late-stage clinical trials for treating specific types of rapid heart rhythm conditions.

Ask drillr about Milestone Pharmaceuticals Inc. →

ProfitabilityView details →

Gross Margin

94.58%

Net Margin

−3585.62%

EBITDA Margin

−3124.58%

ROE (TTM)

−461.14%

ROA (TTM)

−46.26%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

—

EPS YoY

+18.82%

FCF YoY

−51.44%

Revenue CAGR 3Y

−32.38%

EPS CAGR 3Y

−11.94%

EBITDA YoY

−42.88%

EarningsView details →

EPS (Actual)

−$0.21

EPS Surprise

−7.69%

Beats (12Q)

7/12

Next Q EPS Est

−$0.22

Avg Surprise (4Q)

−100.13%

Rev Surprise

−31.55%

Capital & dividendView details →

Debt/Equity

7.79x

Current Ratio

8.13x

Quick Ratio

7.92x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.34M

Net Income (TTM)

−84.01M

Op. CF (TTM)

−61.18M

Next earningsNov 11, 2026 →

Latest newsMore news →

China's National Medical Products Administration approved the launch of Milestone Pharmaceuticals Inc.'s etripamil nasal spray (brand name: Xingbituo) for treating acute episodes of paroxysmal supraventricular tachycardia in adults.2d ago

Milestone Pharmaceuticals initiated the pivotal Phase 3 ReVeRA-301 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).14d ago

Similar companies

NRx Pharmaceuticals, Inc.NRXP Tenaya Therapeutics, Inc.TNYA Biomea Fusion, Inc.BMEA OnKure Therapeutics, Inc.OKUR Unicycive Therapeutics, Inc.UNCY Inovio Pharmaceuticals, Inc.INO Find similar companies →

Latest newsMore news →

China's National Medical Products Administration approved the launch of Milestone Pharmaceuticals Inc.'s etripamil nasal spray (brand name: Xingbituo) for treating acute episodes of paroxysmal supraventricular tachycardia in adults.2d ago Milestone Pharmaceuticals initiated the pivotal Phase 3 ReVeRA-301 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).14d ago